G-BA source · retrieved 2026-08-05
Structured conclusion
1 source-verified result
Patient group
Jugendliche von 12 bis 17 Jahren mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine kontinuierliche systemische Therapie in Frage kommen
Added benefit not proven
Comparator
Dupilumab (ggf. in Kombination mit topischen Glukokortikoiden (TCS) und/oder topischen Calcineurininhibitoren (TCI))
Decision orientation
4 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
Case context
Listed normative targets
A listed target is not treated as a new directive version unless an official version source exists.
Official document package